Synergy Pharma (SGYP) Misses Q1 EPS Views; Offers Corp. Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. SPY
8. UNH
9. SBUX
10. AXP

Go back to Synergy Pharma (SGYP) Misses Q1 EPS Views; Offers Corp. Update

Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update

May 10, 2016 4:30 PM EDT

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016.

2016 is off to a strong and promising start for Synergy, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of our first new drug application (NDA) for plecanatide in chronic idiopathic constipation (CIC), said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals. We continued to expand the utility and value of our uroguanylin-based... More